Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

68-Ga FAPI 46

Next Previous
Drug Profile

68-Ga FAPI 46

Alternative Names: 68Ga-FAPi-46; [68Ga]FAPI-46

Latest Information Update: 09 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Heidelberg
  • Developer GE Healthcare; SOFIE; University of California
  • Class Antineoplastics; Imaging agents; Quinolines; Radioisotopes; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant-mesothelioma; Pancreatic cancer
  • Phase I/II Sjogren's syndrome
  • No development reported Breast cancer; Cholangiocarcinoma; Gastric cancer; Interstitial lung diseases; Ovarian cancer

Most Recent Events

  • 05 May 2025 Erasmus Medical Center plans a clinical trial for Peritoneal metastases (Diagnosis) (IV) in September 2025 (NCT06957782)
  • 11 Apr 2025 GE Healthcare plans a phase I trial for Solid tumours in USA (IV) (NCT06922825)
  • 01 Mar 2025 Rigshospitalet plans a phase II BEFAST STUDY trial Malignant-melanoma (Diagnosis, Late-stage disease) in Denmark (IV, Injection) in March 2025 (CTIS2023-509549-11-00) (EUCT2023-509549-11-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top